Better Rejection‐Free Survival at Three Years in Kidney Transplant Recipients With Model‐Informed Precision Dosing of Mycophenolate Mofetil

Abstract

The clinical impact of individual dose adjustment of mycophenolate mofetil is still debated, due to conflicting results from randomized clinical trials. This retrospective study aimed to compare 3‐year rejection‐free survival and adverse effects between adult kidney transplant recipients (KTRs) with or without mycophenolate mofetil model‐informed precision dosing (MIPD). MIPD is defined here as mycophenolic acid area under the curve (AUC0–12h) estimation using a limited sampling strategy, pharmacokinetic models and Bayesian estimators; dose recommendation to reach AUC0–12h = 45 mg.h/L; using a widely used online expert system. The study, nested in two multicenter prospective cohort studies, focused on patients who received a mycophenolate drug and were followed up for 1–3 years. Mycophenolate mofetil MIPD was prescribed as per local practice, on a regular basis, when deemed necessary, or not at all. The MIPD group included 341 KTRs and the control group 392. At 3 years, rejection‐free survival was respectively 91.2% and 80.6% (P < 0.001) and the cumulative incidence of rejection 5.08% vs. 12.7% per patient × year (hazard ratio = 0.49 (0.34, 0.71), P < 0.001), corresponding to a 2.5‐fold reduction. Significant association with rejection‐free survival was confirmed in patients at low or high risk of rejection (P = 0.017 and 0.013) and in patients on tacrolimus, but not on cyclosporine (P < 0.001 and 0.205). The mycophenolate mofetil MIPD group had significantly more adverse effects, but most occurred before the first AUC0–12h, suggesting some may be the reason why MIPD was ordered.